| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| navicixizumab | delta-like protein 4 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fallopian Tube Carcinoma[MeSHID:D005185] Malignant Neoplasms[MeSHID:D009369] Colorectal Cancer[MeSHID:D015179] Malignant neoplasm of ovary[MeSHID:D010051] |
10.61 | phase 1 | unknown |
| navicixizumab | vascular endothelial growth factor a | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fallopian Tube Carcinoma[MeSHID:D005185] Malignant Neoplasms[MeSHID:D009369] Colorectal Cancer[MeSHID:D015179] Malignant neoplasm of ovary[MeSHID:D010051] |
0.84 | phase 1 | unknown |
| click here to return to the previous page | ||||||||